Blueprint gets green light on PhI studies; Eyegate inks Valeant deal; pSivida sees positive results in PhII eye study;

@FierceBiotech: Roche hustles to FDA with PhII PD-L1 cancer success for 'breakthrough' star atezolizumab. News | Follow @FierceBiotech

@JohnCFierce: You want to see why execs are leaving Big Pharma for biotech? It's where the money is. Report | Follow @JohnCFierce

@DamianFierce: Actual line: "Sorrento recently entered into a definitive agreement with NantPharma to acquire the rights for Cynviloq™ from Sorrento." | Follow @DamianFierce

> The FDA has OK'd two Phase I studies for Blueprint Medicines' two lead drugs. Release

> Waltham, MA-based EyeGate struck a licensing deal with Valeant giving the pharma company worldwide commercial and manufacturing rights to its EyeGate II Delivery System and EGP-437 combination product for uveitis. The deal comes with a private package of potential milestones and an upfront payment. Release

> Watertown, MA-based pSivida Corp. announced positive top line results from a Phase II study of pSivida's Medidur for uveitis affecting the posterior of the eye. Release

> Jersey City, NJ-based Aoxing Pharmaceuticals says that its sublingual tablets of Buprenorphine/Naloxone for opioid dependence delivered promising results in a study, setting the company on track to a filing with China's regulatory authorities. Release

Medical Device News

@FierceMedDev: ICYMI: Magic material: graphene protects chemotherapy, but silver-lined catheters break it down. Article | Follow @FierceMedDev

@StacyALawrence: Aum Cardio raises $5M to back hand-held, in-office CAD Dx device. Article | Follow @StacyALawrence

@EmilyWFierce: The experience of having your blood drawn by Theranos, as laid out by @danmunro. More | Follow @EmilyWFierce

> German prosthetics company mulls IPO for 2017. Story

> U.S. House passes provision to keep tabs on medical devices used on patients. Article

Pharma News

@FiercePharma: Did squirrels pass a killer virus to people? FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Which companies had highest comped CEOs? Hint, most are U.S. and did not necessarily make the most money. Special report | Follow @EricPFierce

@CarlyHFierce: I triple-dog-dare someone to make this new creepy-as-hell $GSK vaccine ad their Twitter pic. Story | Follow @CarlyHFierce

> Otsuka, Lundbeck bag blockbuster FDA approval for long-acting antipsychotic Rexulti. More

> European safety watchdog digs into HPV vaccines again. Article

Animal Health News

> FDA cracks down on Vegas firm selling unapproved kidney drug for dogs and cats. Article

> Perdue ditches all antibiotics for new chicken line, General Mills goes cage-free. Report

> Did squirrels pass a killer virus to people? More

> Senate committee, USDA, poultry producers meet to discuss deadly U.S. avian flu outbreak. Story

> Sweden's Oasmia regains rights to cancer drugs from Zoetis, files for $23M IPO. Article

Biotech IT News

> 21st Century Cures Act clears House with data sharing, standardization sections intact. Story

> Genomics vs YouTube: Which will have the greater computing requirements in 2025? More

> GSK working to build Apple's ResearchKit into its clinical trials. Report

> Financially motivated hackers break into 3 major pharma companies in 18 months. Article

> Core Informatics snags $17.5M to fuel lab software land grab. Story

Pharma Marketing News

> Novartis off to scorching start with Copaxone generic Glatopa. Article

> Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med. Item

> For Entresto rollout, Novartis marketing mixes tried-and-true with new-and-different. Story

> How does the Keytruda-Opdivo marketing battle stack up? More

> GSK's big, bad whooping cough vaccination campaign bares its teeth. Article

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.